Skip to main content

Table 2 Contingency analysis of cytoplasmic phosphorylated RKIP (c-pRKIP), nuclear phosphorylated RKIP (n-pRKIP) and nuclear STAT3 (n-STAT3) expression and tumor Grade and LVI status

From: RKIP phosphorylation and STAT3 activation is inhibited by oxaliplatin and camptothecin and are associated with poor prognosis in stage II colon cancer patients

Marker

Grade

p-value

LVI

p-value

 

Low

High

 

Absent

Present

 

c-pRKIP

n (%)

n (%)

0.024

n (%)

n (%)

0.29

0, 1+, 2+

46 (74%)

16 (26%)

 

55 (89%)

7 (11%)

 

3+

59 (89%)

7 (11%)

 

62 (94%)

4 (6%)

 

n-pRKIP

n (%)

n (%)

0.399

n (%)

n (%)

0.06

0

16 (89%)

2 (11%)

 

18 (100%)

0 (0%)

 

1+, 2+, 3+

90 (81%)

21 (19%)

 

100 (90%)

11 (10%)

 

n-STAT3

n (%)

n (%)

0.064

n (%)

n (%)

0.038

0

19 (95%)

1 (5%)

 

20 (100%)

0 (0%)

 

1+, 2+, 3+

86 (80%)

22 (20%)

 

96 (89%)

12 (11%)

 
  1. The numbers and the percentages of cases are provided.